Identification of expressed genes characterizing long-term survival in malignant glioma patients
- 1 May 2006
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 25 (44) , 5994-6002
- https://doi.org/10.1038/sj.onc.1209585
Abstract
Better understanding of the underlying biology of malignant gliomas is critical for the development of early detection strategies and new therapeutics. This study aimed to define genes associated with survival. We investigated whether genes coupled with a class prediction model could be used to define subgroups of high-grade gliomas in a more objective manner than standard pathology. RNAs from 29 malignant gliomas were analysed using Agilent microarrays. We identified 21 genes whose expression was most strongly and consistently related to patient survival based on univariate proportional hazards models. In six out of 10 genes, changes in gene expression were validated by quantitative real-time PCR. After adjusting for clinical covariates based on a multivariate analysis, we finally obtained a statistical significance level for DDR1 (discoidin domain receptor family, member 1), DYRK3 (dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 3) and KSP37 (Ksp37 protein). In independent samples, it was confirmed that DDR1 protein expression was also correlated to the prognosis of glioma patients detected by immunohistochemical staining. Furthermore, we analysed the efficacy of the short interfering RNA (siRNA)-mediated inhibition of DDR1 mRNA synthesis in glioma cell lines. Cell proliferation and invasion were significantly suppressed by siRNA against DDR1. Thus, DDR1 can be a novel molecular target of therapy as well as an important predictive marker for survival in patients with glioma. Our method was effective at classifying high-grade gliomas objectively, and provided a more accurate predictor of prognosis than histological grading.Keywords
This publication has 26 references indexed in Scilit:
- Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytomaOncogene, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- DNA-microarray analysis of brain cancer: molecular classification for therapyNature Reviews Neuroscience, 2004
- Gene expression profiling identifies molecular subtypes of gliomasOncogene, 2003
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003
- Identification of molecular subtypes of glioblastoma by gene expression profilingOncogene, 2003
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- DYRK3 Activation, Engagement of Protein Kinase A/cAMP Response Element-binding Protein, and Modulation of Progenitor Cell SurvivalJournal of Biological Chemistry, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Discoidin Domain Receptor 1 Is Activated Independently of β1 IntegrinPublished by Elsevier ,2000